Article Text

Download PDFPDF
Pulmonary arterial hypertension: promising advances and remaining challenges
  1. Karim El-Kersh,
  2. John D Dickinson
  1. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
  1. Correspondence to Dr John D Dickinson, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA; jdickins{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Pulmonary arterial hypertension (PAH) diagnosis and management have evolved over the years. Despite advances in management that resulted in an overall improvement of disease outcomes, there remain challenges to be addressed, including more accurate disease phenotyping, earlier diagnosis with better screening, and novel therapeutic approaches. In this issue of the Journal of Investigative Medicine, Deshwal1 review the changing landscape of PAH with a special emphasis on clinical risk assessment as a tool to guide treatment options.

Further disease phenotyping is needed beyond the current Sixth World Symposium on Pulmonary Hypertension subgroups to better understand the disease and response to therapies.2 The Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics program aims to compare ‘omics’ data to better phenotype patients with pulmonary vascular disease to advance a precision medicine approach.3 4 The lack of consistent response to multiple PAH-specific therapies across the PAH spectrum may be …

View Full Text


  • Contributors KE-K wrote the editorial. JDD edited and revised the editorial.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests KE-K served on advisory boards for United Therapeutics and Actelion and as consultant for Acceleron Pharma, and received institutional funded research from United Therapeutics and Actelion.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles